ArticleCureus2026
Adjuvant Mood Stabilisers for Long-Term Management of Treatment-Resistant Schizophrenia: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment-resistant schizophrenia (TRS) is associated with persistent psychotic symptoms, protracted hospital admissions, and significant functional impairment despite adequate trials of antipsychotic treatment. Optimisation of antipsychotic medication, particularly clozapine-based treatment regimens, alongside multidisciplinary inpatient rehabilitation, is one of the mainstays for improving outcomes in difficult-to-treat schizophrenic presentations. Persistent symptoms despite clozapine treatment have been shown to improve with adjunctive mood stabilisers, especially when there is affective instability. This retrospective case report describes individuals with long-standing TRS receiving care in an inpatient rehabilitation service. Adjunctive mood stabiliser medication was introduced as part of pharmacological optimisation alongside structured rehabilitative interventions for maximum symptom control. Following this approach, gradual improvements were observed in symptom control and engagement with rehabilitation. These cases highlight the potential benefit of mood stabiliser augmentation, such as Lamotrigine or Valproate, in difficult-to-treat presentations, particularly where there is a prominent affective component. Integrated multidisciplinary inpatient rehabilitation and pharmacological optimisation are essential for achieving sustained symptom control and functional recovery in complex psychiatric presentations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.